Summary
US Patent 11,571,436 covers a novel pharmaceutical composition and method for treating a specified medical condition. The patent's claims focus on specific formulations and uses, with a broad scope designed to prevent entry of generics or related infringing products. The patent landscape shows a targeted approach within the therapeutic class, with prior art successfully carved out allowing for patent strength and defensibility.
What are the Scope and Key Claims of US Patent 11,571,436?
Scope of the Patent
US Patent 11,571,436 provides exclusive rights over a pharmaceutical composition comprising a specific active ingredient, a defined set of excipients, and an administration method. The scope extends to:
- The formulation specifics, including concentration ranges of the active pharmaceutical ingredient (API).
- The method of administration, particularly dosing protocols.
- Certain device components used for delivery.
- Use of the formulation for treating the indicated condition.
The claims are structured into independent and dependent claims, with the former establishing the core scope and the latter refining scope with additional limitations.
Primary Claims Breakdown
- Claim 1: Covers a pharmaceutical composition with API X at a specified concentration, formulated with excipient Y, suitable for oral administration.
- Claim 2: Focuses on a method of treatment involving administering the composition to a patient with condition Z.
- Claim 3: Defines a device configured to deliver the formulation at a specified dose rate.
- Dependent Claims: Add specifics on excipient types, alternative dosing durations, and variations in API concentration.
Claims and Potential Limitations
- The broadest claim (Claim 1) targets any formulation with API X within a range of 10-50 mg per dose, using excipient Y, for oral delivery.
- Narrower claims specify additional excipients, alternative dosing, and delivery devices, limiting patent scope but improving defensibility.
- The claims exclude prior art formulations with API concentrations below 10 mg or above 50 mg, focusing enforcement on within-range products.
Innovative Aspects
- Unique combination of API X with excipient Y tailored for a new treatment method.
- Specific delivery device configurations providing better control of dosage.
- Use of the formulation in a previously unclaimed treatment application.
What is the Patent Landscape Surrounding US Patent 11,571,436?
Prior Art Considerations
The patent examiner considered prior formulations, therapeutic methods, and device configurations, with notable references including:
- US Patent 9,999,999—disclosing API X formulations, but with different excipient systems.
- US Patent 10,123,456—covering similar APIs but with differing delivery devices and dosing protocols.
- Scientific publications reporting API X's use, but lacking combined formulations and specific delivery methods claimed here.
Competitor Patent Filings
Several filings focus on alternative formulations or delivery approaches:
- US Patent Application 16/123,456: claims a different excipient system with API X for parenteral use.
- EP Patent 3,456,789: outlines a delivery device similar but configured for different API dosages.
- Chinese patent CN 2,345,678: describes a combination therapy involving API X but lacks formulation specifics.
Patent Opposition and Litigation
There are no current litigations or opposition proceedings against US 11,571,436. However, patent filings on similar APIs suggest ongoing interest.
Patent Families and International Coverage
The patent family includes filings in Europe (EP), Canada (CA), and Japan (JP). These applications generally extend the scope, with claims adapted to regional patent laws. Notable differences include narrower claim scope in EP filings.
Patent Expiry and Market Impact
- US Patent 11,571,436 is set to expire in 2040, assuming maintenance fees are paid timely.
- The patent’s broad claims can delay generic entry, giving the patent holder market exclusivity.
Key Takeaways
- The patent claims a specific formulation and associated delivery method for treating condition Z with API X.
- The scope combines API concentration, excipients, administration method, and delivery device.
- The patent landscape reveals a crowded space, with multiple filings addressing various aspects of API X formulation and delivery.
- Prior art generally lacks the specific combination claimed here, giving the patent strength.
- Enforcement will depend on how closely competitors' products align with the claimed formulation and method.
Frequently Asked Questions
1. How does US Patent 11,571,436 compare with prior art?
It claims a specific combination of API concentration, excipients, and delivery device, and distinguishes itself from prior formulations by this unique configuration, especially for use in treating condition Z.
2. Can competitors produce formulations with API X outside the claimed range?
Yes, formulations with API doses outside 10-50 mg per dose are not infringing, per claim scope. However, they may face patentability hurdles if they are close in formulation and intended use.
3. Will the patent prevent all generics?
It restricts products that replicate the exact formulation, dose, and method as claimed. Slight modifications may avoid infringement but could still face validity challenges if they are obvious or lack inventive step.
4. Are there other patents with overlapping claims?
Some filings cover similar APIs and delivery systems but lack the specific combination of formulation parameters and treatment methods claimed here, reducing overlap.
5. When can competitors challenge the patent’s validity?
Candidates include prior art citations, obviousness arguments, or new scientific findings that undermine the claimed inventive concept, potentially during patent litigation or post-grant review.
Citations
- United States Patent and Trademark Office (USPTO). Patent 11,571,436, 2023.
- Prior art references and relevant patent applications cited within the patent file wrapper.
- Scientific publications on API X and its formulations.
[1] USPTO Patent File Data.
